Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news


From To
Smoking reduces survival after liver cancer diagnosis for people with viral hepatitis

People with viral hepatitis who smoked were three times more likely to die after being diagnosed with liver cancer (hepatocellular carcinoma, HCC), according to a

18 January 2018
Keith Alcorn
Hepatitis C treatment highly effective in harder-to-treat people with HIV co-infection, Spanish real-life study shows

Hepatitis C virus (HCV) treatment using direct-acting antivirals (DAAs) is highly effective and safe in harder-to-treat people with HIV co-infection, Spanish researchers report in AIDS.

16 January 2018
Michael Carter
India to launch national program to control viral hepatitis and aims to negotiate lower drug prices

The health ministry is set to roll out a National Program for the Control of Viral Hepatitis from the 2018-19 financial year. An antiviral treatment that costs anywhere between $63,000 and $94,000 for the full course in the USA and Europe is to be provided free of cost at all government health organizations.

09 January 2018
Pharma Letter
England: 25,000 Hepatitis C patients receive new treatments

As we go into the New Year, the Hepatitis C (HCV) programme is set to pass a major milestone. The number of patients in England having received the new direct acting antiviral treatments will pass the 25,000 mark. The 22 Operational Delivery Networks (ODNs) across the country were tasked to expand rates of treatment by 25 per cent from April this year, and nine months on are delivering at over 90 per cent of those goals.

08 January 2018
NHS England
HCV Genotype 6 Responds to 8-Week Oral Treatment

The successful treatment of hepatitis C virus genotype 6 (HCV-GT6) with a non-interferon-based fixed dose oral regimen of ledipasvir and sofosbuvir (LDV/SOF) bodes well for treating HCV in Southeast Asia, where newer pangenotypic agents are not available to treat this region's most prevalent genotype.

02 January 2018
Should uninfected patients accept hepatitis C-infected livers to reduce waiting time?

A modeling study by Massachusetts General Hospital investigators finds that the availability of directly-acting antiviral drugs to treat hepatitis C virus infection could allow the transplantation of livers from HCV-positive donors into HCV-negative recipients without posing undue risk.

20 December 2017
Eurekalert Inf Dis
Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

A combination of providing clean needles and syringes and offering safer oral therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection.

08 December 2017
National Institute for Health Research
MSF: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

Medecins Sans Frontieres (MSF) has begun treatment for hepatitis C with people who are co-infected with hepatitis C and HIV in Mykolaiv region, in southern Ukraine, where prevalence of HIV is two times higher than the average across the country.

04 December 2017
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the US price: report

It was expected that Gilead would deeply discount Sovaldi for the Chinese market, but the reported price is still much higher than in other emerging markets where it has licensed the drug to generics makers.

29 November 2017
More work and lower drug prices are needed to eliminate hepatitis C worldwide

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do this more people need to be tested and treated

29 November 2017
Liz Highleyman
← First12345...232Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.